Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$95.03+2.6%$64.53$29.18▼$105.00$620.27M1.46147,972 shs177,531 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics-2.08%+12.82%+42.36%+67.16%+158.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$95.03+2.6%$64.53$29.18▼$105.00$620.27M1.46147,972 shs177,531 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics-2.08%+12.82%+42.36%+67.16%+158.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNPRMonopar Therapeutics 3.00Buy$108.7514.44% UpsideCurrent Analyst Ratings BreakdownLatest MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026MNPRMonopar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$104.00 ➝ $117.006/29/2026MNPRMonopar Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/29/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.006/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)Latest MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNPRMonopar TherapeuticsN/A56.0456.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipMNPRMonopar Therapeutics9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableMNPR HeadlinesRecent News About These CompaniesMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson DiseaseJune 30 at 8:00 AM | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street ZenJune 27, 2026 | americanbankingnews.comMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson DiseaseJune 26, 2026 | globenewswire.comMonopar Shareholders Approve Directors, Pay and Incentive PlanJune 23, 2026 | tipranks.comMonopar Therapeutics Inc (MNPR) Receives a Buy from Piper SandlerJune 16, 2026 | theglobeandmail.comWall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to TradeJune 15, 2026 | zacks.comMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026June 1, 2026 | globenewswire.comMNPR stock rallies after hours as experimental drug shows rapid copper balance improvement in genetic disorderMay 19, 2026 | msn.comMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMay 19, 2026 | globenewswire.comMonopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson DiseaseMay 14, 2026 | quiverquant.comQMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 14, 2026 | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth PlansMay 4, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO)April 22, 2026 | theglobeandmail.comMonopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026April 19, 2026 | quiverquant.comQMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026April 19, 2026 | globenewswire.comMonopar Therapeutics Inc (MNPR) Gets a Buy from JonesTradingApril 10, 2026 | theglobeandmail.comMonopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson DiseaseMarch 27, 2026 | quiverquant.comQMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateMarch 27, 2026 | globenewswire.comMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy OfficerMarch 2, 2026 | globenewswire.comMonopar Therapeutics scores relative strength rating upgrade; hits key thresholdFebruary 24, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR Company DescriptionsMonopar Therapeutics NASDAQ:MNPR$95.03 +2.44 (+2.64%) Closing price 04:00 PM EasternExtended Trading$94.88 -0.15 (-0.16%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
